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Abstract 
Cobalt complexes with semi- and thiosemicarbazones of 8-quinolinecarboxaldehyde have 
been synthesized and characterized by X-ray diffraction analysis. These novel complexes, 
and previously synthesized cobalt complex with selenium based selenosemicarbazone ligand, 
showed myeloid differentiating activty on All Trans  Retinoic Acid resistant HL-60 acute 
myeloid leukaemia cells.  They also showed varying levels of cytotoxicity on five human 
tumor cell lines: cervix carcinoma cells (HeLa), lung adenocarcinoma cells (A549), 
colorectal adenocarcinoma cells (LS-174), breast carcinoma cells (MDA-MB-361), chronic 
myeloid leukaemia (K562) as well as one normal human cell line: fetal lung fibroblast cells 
(MRC-5). Leukaemia differentiation was most strongly induced by metal-free oxygen ligand 
and the selenium ligand, whilst the latter and the cobalt(II) complex with oxygen ligand 
showed the  strongest dose-dependent cytotoxic activity. In four out of five investigated 
tumor cell lines, this was of the same order of magnitude as cisplatin. These best compounds 
however, had lower toxicity on non-transformed MRC-5 cells than cisplatin. 
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1. Introduction 
Today  cancer  is  a    leading  cause  of  death  worldwide   with  2030  projections 
estimated  at  13.1  million  deaths.1  The mainstay of treating widely dispersed (and therefore 
likely fatal) cancer is chemotherapy, which can be severely toxic, so the goal of much  
current research is to identify novel (safer and more effective) treatments for  neoplastic 
conditions with the hope of decreasing  morbidity and mortality. This has resulted in a large 
move towards targeted therapies for cancer, which aim to be less harmful to healthy 
proliferating cells in general. One such option is differentiation therapy, where malignant 
cells are stimulated to differentiate, thus maturing and entering the natural apoptotic 
pathways.2,3 Leukaemia has been the main success story of differentiation therapy so far.  
This group of haematological neoplasia are characterized  by  the  unregulated proliferation 
of hematopoietic progenitor cells that fail to differentiate into mature cells leading to  
anaemia, immunocompromise  and  bleeding  disorders often times resulting in fatality.  
Acute myeloid leukaemia (AML) is the type with the worst prognosis, with 10 year survival 
rates of around 5% in older adults and around 50% in younger ones.4  Cytogenetic analysis is 
essential in prognosis and treatment of AML nowadays.5 Acute promyelocytic leukaemia  
(APL), one of the variants  of AML, shows a translocation between  the  long  arms  of 
chromosomes,  15  and  17,  lead  to  the  production  of  an abnormal fusion protein (PML-
RARα) made from the parts of 2 genes on the 2 separate chromosomes.6,7  This fusion protein 
interferes with DNA transcription, effectively blocking the differentiation of promyelocytes 
into myelocytes and causing the former’s accumulation at the expense of functional fully 
differentiated white blood cells.8  This disease of young adults was almost invariably fatal,  
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due to a severe coagulopathy until the revolutionary  introduction  of  ATRA  (All Trans  
Retinoic Acid)  as  a  treatment  of  APL.9 The drug which is a ligand of the retinoic acid 
receptor α component of the fusion protein, when given in supra-physiological 
concentrations, is able to relieve the transcription block posed by the PML-RARα  fusion 
protein and effectively  induce  differentiation.10 Together with a low dose of traditional 
chemotherapy, this has managed to achieve a cure rate of around 80%.11 The lack of toxic 
side-effects seen in standard chemotherapy is an added benefit.12 Unfortunately,  ATRA  
works effectively only  on  the  APL genetic  subtype  of  acute myeloid leukaemia, although 
some  efficacy has been seen on osteosarcoma and glioma cells or tumours.13,14  Due to this 
success story, however, extensive research is now being directed towards finding compounds 
which can cause differentiation in other types of immature leukemic cells.15  Initial testing of 
therapeutic candidates makes use of cell lines derived from leukemic patients which are 
easily available and can act as a shared standard across many research laboratories. Here we 
focus on the HL-60 cell line as our model.  
(Chalcogen)semicarbazones, condensation products of (chalcogen)semicarbazides and 
carbonyl compounds, have been a subject of interest in coordination chemistry for many 
years. Versatile modes of coordination of this class of ligands have been reported.16-19 They 
can coordinate to metal ions bidentately via chalcogen donor and imine nitrogen atoms, but 
the coordination ability may be extended if a parent carbonyl compound possesses other 
suitable donor atoms. This general class of compounds has been shown to possess a wide 
range of bioactive properties, including antitumor activity.20-37 In fact 
(chalcogen)semicarbazones with activities comparable to standard anticancer drugs, like cis-
diammindichloridoplatinum(II) (cisplatin, CDDP), have been developed. A few 
comprehensive comparative studies of (chalcogen)semicarbazones and their complexes 
Page 4 of 32MedChemComm
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
20
 O
ct
ob
er
 2
01
6.
 D
ow
nl
oa
de
d 
by
 T
uf
ts 
U
ni
ve
rs
ity
 o
n 
23
/1
0/
20
16
 2
1:
44
:4
5.
 
View Article Online
DOI: 10.1039/C6MD00501B
  
5 
 
pointed out the importance of the chalcogen donor atom identity for biological activity.26,30,38 
Among three types of (chalcogen)semicarbazones, thiosemicarbazones have been studied to a 
greater extent than semicarbazones and selenosemicarbazones. Some results indicated that 
sulphur compounds are more active in comparison to oxygen analogues, which showed a 
rather limited spectrum of biological activity.24 These thiosemicarbazones are also more 
stable and safer to handle than their selenium analogues.37,39,40 Selenosemicarbazones and 
their metal complexes have been an area of  our particular interest for years.31-47,41,42   
Research suggests that  the mechanisms of cytotoxicity of these compounds may include the 
production of reactive oxygen species and oxidative stress in the complexes with 2-
quinolinecarboxaldehyde selenosemicarbazone.37 
In the current study we used 8-quinolinecarboxaldehyde-based 
(chalcogen)semicarbazones as ligands (Scheme 1), providing a detailed spectroscopic and 
structural characterization (X-ray diffraction, XRD) of the novel cobalt complexes with 
oxygen and sulphur based ligands. Cobalt was chosen as a central metal ion since 
coordination of (chalcogen)semicarbazones to cobalt often results in complexes with 
activities higher than the activity of standard anticancer drugs such as cisplatin.33, 43-46 We 
analysed the effects of (chalcogen)semicarbazones and  corresponding cobalt complexes on 
the differentiation of  high passage number (70+) HL-60  cells which are known to be poorly  
responsive to ATRA-induced differentiation.47 We further test the general cytotoxic effects of 
these compounds on a number of tumor cell lines and on normal cells and perform some 
analysis into the cell cycle perturbations induced. 
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Scheme 1. Schematic structure and atomic numbering scheme of (chalcogen)semicarbazone 
ligands: H8qaSC, H8qaTSC and H8qaSeSC. 
 
2. RESULTS & DISCUSSION 
2.1. General 
 (Chalcogen)semicarbazone cobalt complexes with H8qaSC and H8qaTSC ligands 
were synthesized by template reactions starting from metal salts, 8-quinolinecarboxaldehyde 
and corresponding (chalcogen)semicarbazide (mole ratio 1 : 2 : 2, respectively). The same 
products were obtained also by direct reactions of metal salts and the ligands in a 1 : 2 molar 
ratio. The composition of the products was not affected by the change of the molar ratio of 
the reacting species. The complexes are soluble in MeOH, EtOH, MeCN, DMF and DMSO at 
room temperature. Molar conductivity measurements showed that the complex with oxygen 
ligand H8qaSC is 1 : 2 electrolyte, while complex with sulfur ligand H8qaTSC is 1 : 1 
electrolyte. Elemental analysis showed that complex with oxygen ligand contains two neutral 
H8qaSC ligand molecules, two chloride ions and two water molecules. This complex has a 
room-temperature magnetic moment of 1.80 µB, consistent with just one paramagnetic Co(II) 
center, while the other complex is diamagnetic in nature and the central metal ion in the 
complex with sulfur ligand  is Co(III). Based on these data, as well as spectroscopic data and 
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X-ray structural analysis (vide infra) the general formula of two novel complexes can be 
written as [Co(H8qaSC)2]Cl2·2H2O (1) and [Co(8qaTSC)2]ClO4·DMSO (2). 
Synthesis of cobalt(III) complex with oxygen ligand H8qaSC was unsuccessful even 
when a stream of air was passed through the reaction mixture for 3 h. Similarly, in the case of 
related 2-formyl, 2-acetyl, 2-benzoylpyridine N(4)-cyclohexylsemicarbazones, cobalt(II) 
complexes with neutral ligands were obtained, whereas with the analogous 
thiosemicarbazones, cobalt(III) complexes with anionic form of the ligands were obtained.48  
It is anticipated that oxidation reaction of cobalt(II) to cobalt(III) species consists of two main 
steps: (1) the reversible formation of a dioxygen adduct (µ-peroxo-bridged cobalt compound) 
and (2) its irreversible decomposition to related cobalt(III) complexes,  where the redox 
rearrangement reactions can be classified as metal-centered oxidations and ligand-centered 
oxidative dehydrogenations.49,50 It is well known that the octahedral hexaaquacobalt(II) ion is 
stable to aeral oxidation, but data on standard reduction potential for a variety of cobalt(III) 
complexes showed the stabilization of the +3 oxidation state relative to the +2 as the ligands 
are changed from O- to N-donors.51 In the case of (chalcogen)semicarbazones derived from 
8-quinolinecarboxaldehyde, it can be assumed that combination of favorable thermodynamic 
and kinetic factors allows for facile synthesis of cobalt(III) complexes with heavier 
chalcogens, as opposed to cobalt(II) complex with O analogue. 
2.2. Description of structures 
Crystal data and structure determination results are summarized in Table 1. Single 
crystals of the ligand H8qaTSC were obtained by slow diffusion of ethanol into DMSO 
solution of the ligand. Crystal structure of the ligand H8qaTSC has been previously 
determined,52 but it was not deposited in The Cambridge Crystallographic Data Centre 
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(CCDC). The structure was re-investigated and it corresponds to that previously determined, 
except that we have obtained a better model with a slightly lower R factor value. 
 
Table 1. Crystal data and structure refinement for the ligand H8qaTSC and complexes 1 and 
2 
 H8qaTSC 1 2 
Crystal data 
Empirical formula C11H10N4S C22H20CoN8O2· 
2Cl·2(H2O) 
C22H18CoN8S2·ClO4· 
C2H6SO 
Formula weight 230.29 594.32 695.02 
Crystal system  
space group 
Monoclinic 
P21/c 
Monoclinic 
C2/c 
Triclinic 
P¯1 
a, b, c (Å) 8.9464 (9), 12.8728 (11), 
9.7816 (7) 
21.752 (3), 10.0815 (9), 
13.905 (2) 
10.3016 (6), 10.5421 (7), 
14.5516 (10) 
α, β, γ (°) 90, 95.947 (8), 90 90, 124.39 (2), 90 80.662 (6), 89.829 (5), 
65.733 (6) 
V (Å3) 1120.43 (17) 2516.1 (8) 1418.02 (17) 
Z 4 4 2 
µ (mm-1) 0.27 0.94 0.97 
Crystal size (mm) 0.20 × 0.18 × 0.12 0.15 × 0.12 × 0.09 0.09 × 0.08 × 0.08 
 Tmin, Tmax 0.697, 1.000 0.585, 1.000 0.955, 1.000 
No. of measured, 
independent and 
observed [I > 2σ(I)] 
reflections 
16892 
2551  
2116   
18343  
2881  
2365   
20909  
6165  
4897   
Rint 0.032 0.049 0.042 
(sin θ/λ)max (Å
-1) 0.650 0.650 0.639 
R[F2 > 2σ(F2)] 0.039   0.042   0.046   
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wR(F2) 
S 
0.110   
1.06 
0.103  
1.05 
0.126   
1.03 
No. of reflections 2551 2881 6165 
No. of parameters 157 188 389 
∆〉max, ∆〉min (e Å
-3) 0.21, –0.33 0.40, –0.26 0.53, –0.53 
In the molecular structure of complex 1, a [Co(H8qaSC)2]
2+ cation crystallizes with 
two chloride anions and two water molecules. The cobalt(II) ion lies on a twofold rotation 
axis, hence the asymmetric unit of 1 consists of  a half of the complex cation, one chloride 
ion and one water molecule (Figure 1a). In the complex cation, the cobalt(II) metal center is 
coordinated to two tridentate neutral H8qaSC ligands, giving rise to a chiral octahedral 
arrangement. Complex 1 is nonetheless a racemate, since it crystallizes in the 
centrosymmetric C2/c space group. Chelation occurs by means of quinoline (N1, N1i) and 
imine (N2, N2i) nitrogens and by the oxygen donors (O1, O1i), where i = ‒x, y, 1.5 ‒ z, in a 
mer geometry constrained by the ligand’s planarity.  Figure 1b reports the molecular structure 
of [Co(H8qaSC)2]
2+ in 1, while Table S1 (Electronic Sympplementary Information, ESI) 
reports the coordination geometry. The coordinative bond lengths in 1 are similar to the 
respective bonds in analogous N-heteroaromatic semicarbazone cobalt(II) complexes: bis{1-
[(E)-2-pyridinylmethylidene]semicarbazide}cobalt(II) diperchlorate monohydrate (CSD 
refcode ATUNEI),53 and bis[bis(2-pyridyl)ketone semicarbazonato-N,N',N'']cobalt(II) 
dinitrate monohydrate (CSD refcode WEJNOO).54 The crystal packing (Figure S1 and Table 
S2, ESI) is based on a 3D hydrogen bond network involving terminal NH2 groups, N‒H 
groups, chloride ions and crystal water molecules.  
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Figure 1. Asymmetric unit of complex 1 (a) and perspective view and labeling of the 
molecular structure of [Co(H8qaSC)2]
2+ in 1 (b). Thermal ellipsoids are at the 50% 
probability level. Equivalent atoms are generated by the transformation i = ‒x, y, 1.5 ‒ z. 
 
XRD shows that in the case of complex 2 two deprotonated H8qaTSC ligands are 
coordinated to the cobalt(III) ion, while the outer sphere of the complex consists of 
perchlorate ion and one DMSO solvent molecule. The octahedral bischelate cation 
[Co(8qaTSC)2]
+ possesses mer geometry. Since the complex crystallizes in the 
centrosymmetric P–1 space group, it is a racemic compound regardless a chiral octahedral 
arrangement of cationic species in 2. Figure 2 shows a perspective view of the complex 
cation in 2, while Table S1 (ESI) reports the most relevant bonding parameters. Monoanionic 
form of H8qaTSC ligand coordinates the metal via the sulfur atom, the quinoline and the 
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imine nitrogen atoms, with the formation of one six-membered and one five-membered 
chelate rings. All metal-donor atom bonds are close to the average corresponding bonds 
found in a search on quinoline thiosemicarbazone-cobalt systems performed through the 
Cambridge Structural Database (CCDC: 734053; 2016 release, v. 5.37 with updates: Nov15, 
Feb16).55 Besides electrostatic interactions between complex cations and counter ions, the 
crystal packing of the complex 2 (Figure S2 and Table S3, ESI) is based on hydrogen bonds 
and π-π stacking interactions of the quinoline rings. The complex 2 is isostructural with 
cobalt(III) complex with selenium ligand  [Co(8qaSeSC)2]ClO4·DMSO (3).
56 
 
 
Figure 2. Perspective view and labeling of the molecular structure of [Co(8qaTSC)2]
+  in 2. 
Thermal ellipsoids are at the 50% probability level. 
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2.3. Spectroscopic characterization 
In the IR spectra of the ligands H8qaSC and H8qaTSC, there are sharp medium 
intensity bands in the region 3315 – 3155 cm–1 which are assigned to the ν(NH2) and ν(NH) 
stretching vibrations. The lack of a large systematic shift of these bands in the IR spectra of 
complexes 1 and 2 (Figures S3 and S4, respectively, ESI) indicates no interaction between 
the terminal nitrogen atom and cobalt ion. The band at 1705 cm‒1 in the spectrum of the 
ligand H8qaSC, which is ascribed to a ν(C=O) vibration, is shifted to 1652 cm‒1 in the 
spectrum of complex 1, suggesting the coordination of the oxygen atom. Coordination of 
azomethine nitrogen to cobalt in 1 is suggested by the shift of the ν(C=N) toward lower 
frequency (1587 cm‒1 in H8qaSC, 1550 cm‒1 in 1). In the IR spectrum of complex 2 there is a 
systematic shift of the ν(C=N) band to higher frequencies in comparison to that in the 
corresponding ligand (1603 cm–1 in H8qaTSC; 1637 cm–1 in 2). As it had been previously 
observed in other complexes with heavier (chalcogen)semicarbazones,19,31‒33,41,42 upon 
coordination of the sulfur/selenium atom, the ν(C=X) band (X = S, Se) was shifted to lower 
frequencies. Also, in the IR spectrum of complex 2, the sharp and strong bands at 1015 cm–1 
and ~ 1090 cm‒1 can be observed, originating from the non-coordinated DMSO molecule and 
perchlorate ion, respectively. In the complex 1, a broad absorption in the region above 3300 
cm–1 was attributed to the lattice water. 
1H and 13C NMR spectroscopy data (Figures S5 and S6, respectively, ESI) confirm 
tridentate coordination of the ligand H8qaTSC in its monoionic form in the complex 2. 
Correlation  of H–C2 with H–C9 and H–C7 in the 2D ROESY spectrum the complex 2 
(Figure S7, ESI), as previously noticed for the Co-selenosemicarbazone complex 3,56 points 
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to the octahedral geometry, which indicates that the geometry of the complex 2 is preserved 
in the solution. 
The electronic absorption spectra of the (chalcogen)semicarbazone ligands exhibited 
three bands in the region 350–220 nm, corresponding to the intra-ligand transitions associated 
with the azomethine, quinoline, and C=X (X = O, S) portions of the ligands (Figure S8, ESI). 
In the spectra of the complexes, the intense absorption bands attributed to the intra-ligand 
transitions within the coordinated ligand moiety and ligand-to-metal charge transfer 
transitions can be observed (Figure S8, ESI). The aqueous solution behavior of complexes 
1‒3 with respect to hydrolysis was studied in DMSO/H2O 1:100 (v/v) solutions at ambient 
temperature over 24 h by UV-Vis spectroscopy. The complexes 1‒3 were stable, as can be 
seen from their electronic absorption spectra (Figure S9, ESI). 
 
 
2.4. Spectrophotometric assays of HL-60 differentiation-inducing and cytotoxic activity  
As myeloid cells approach final maturation, they express and store oxidative 
burst enzymes capable of reducing soluble yellow nitroblue tetrazolium (NBT) into 
blue insoluble formazan crystals. The detection of this activity is therefore an 
indication of early myeloid maturation. Undifferentiated cells continue to proliferate, 
whilst those which entered differentiation will be reduced in number as more mature 
forms of myeloid cells stop proliferating as part of their maturation process. They also 
become capable of NBT reduction. The relative cell number can be assessed by (3-(4,  
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) assay. Therefore, the 
NBT/MTT ratio is used as a screening method to gauge differentiation induction in 
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this model cell line.57 Samples which showed good NBT/MTT ratios were then tested 
by morphologic assessment with Leishman stain (vide infra). 
As can be seen  in Figure 3, the NBT/MTT ratio, a spectroscopic screen for 
state of differentiation,57  shows that  H8qaSC  and its cobalt(II) complex 1  and 
H8qaSeSC and its cobalt(III) complex 3 appear to induce some differentiation (of 
greatly varying extent)  whilst both the thiosemicarbazone ligand H8qaTSC and its 
cobalt(III) complex 2 have relatively little effect. Selenium ligand H8qaSeSC, as well 
as oxygen ligand H8qaSC is effective at inducing differentiation at three days post-
exposure even at 1 µM doses.  After five days of exposure, H8qaSeSC and complexes 
1 and to a lesser extent 3 appear the better differentiating agents.  
Data from MTT assay acquired after 72 h incubation and used to calculate 
NBT/MTT ratio, were also employed to estimate cytotoxic activity of investigated 
compounds on HL60 cells. As it can be seen in Figure S10A (ESI), ligands H8qaSC, 
H8qaSeSC and complex 3 were those which activity reached IC50 concentrations. The 
IC50 value implies that investigated treatment reduced the size of treated population for 
50 % compared to non-treated control but does not obtain information on particular 
mechanism responsible for this effect. In order to evaluate whether cytotoxic activity 
or inhibition of proliferation was the underlying cause, cell cycle analysis on HL60 
cells subjected to IC50 concentrations of H8qaSC, H8qaSeSC and 3 for 72 h was 
further performed to assess the percentages of cells accumulated at the sub-G1 
subpopulation (Figure S10B, ESI).  Compound H8qaSeSC was the only one that 
notably, but still modestly, increased percentage of dead cells, whereas H8qaSC and 
complex 3 barely raised the size of sub-G1 fraction compared to control levels. These 
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results clearly indicate that investigated compounds did not exert cytotoxic activities 
on HL60 cells in a range of applied concentrations. 
 
 
Figure 3.  Indicative differentiation (as expressed by NBT/MTT ratio), relative to the 
same activity of undifferentiated cells (day 0)  and  without treatment after 3 or 5 days 
(indicated as RPMI – medium). Each value is a mean of three replicates and error bars 
indicate the range of values.  
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2.5. Differentiation results – morphology 
The HL-60 cells exposed to the different chemicals being tested were also 
assessed for morphological evidence of differentiation after Leishmann staining to 
visually confirm the effects of differentiation induction. Cells exposed to 
(chalcogen)semicarbazone ligands and their cobalt complexes showed varying pictures 
of differentiation, being clearly different from both positive controls DMSO and PMA, 
as well as from untreated HL-60 cells (Figure 4). This may suggest an incomplete 
differentiation in certain cases, although some features of H8qaSeSC-induced 
differentiation, such as marked granule formation, are not even seen with the positive 
controls. It is interesting that they be combined in future studies with DNA modifying 
agents to enhance their effect.58 Otherwise, as in situation with APL, the combination 
with standard chemotherapy may result in the cells which are induced to differentiate 
being killed off resulting in a remission or even a cure.9  
The ligand H8qaSeSC which showed the strongest induction of NBT activity, 
through spectrophotometry, caused the development of numerous granules in the 
HL60 cells, indicating a strong differentiation towards granulocytes, together with the 
loss on nucleoli in the non-granular cells (Figure 4f).  The same compound has also 
been shown to induce some markers of differentiation in solid tumour cancer stem 
cells.56   
Despite H8qaSC, H8qaTSC and H8qaSeSC having a rather similar structure 
with a sulphur or selenium atom substituting an oxygen atom in the parent compound 
H8qaSC, it appears that these small modifications greatly vary the differentiation-
inducing activity of H8qaSC, with selenium enhancing it and sulphur removing it. 
Selenium is an important trace element in the body and the inclusion of this atom may 
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mimic a selenium-containing natural factor. Zinc-finger transcription factor PLZF is 
known to abnormally repress gene activity in HL-60,59 and selenium is a known 
inhibitor of Zinc-finger transcription factors.60,61 Thus by inhibiting PLZF-dependent 
gene repression may result in differentiation.59,61 This may well be the reason for the 
stronger differentiation induced by H8qaSeSC as opposed to H8qaSC. The 
complexing of the selenium atoms with the cobalt in complex 3, may also then reduce 
this zinc-finger interaction and explain why the complex is less effective. The cobalt 
complex 3 resulted in some changes in nuclear chromatin condensation as well as of 
nuclear cytoplasmic ratios and development of numerous pseudopodia however the 
occasional granular cells also appeared. This, together with clearly lower NBT 
activity, suggests the differentiation induced by the complex is less than by the metal-
free ligand H8qaSeSC, which may relate to the selenium-induced effects being 
suppressed by the very tight binding within the complex. 
Exposure to the oxygen ligand H8qaSC shows smaller sized cells with reduced 
nuclear cytoplasmic ratios as well as evidence of nuclear chromatin condensation also 
indicating a partial differentiation. It is interesting to note that its complex 1 showed 
only minimal differentiation, unlike its strong cytotxic activity to tumour cells (see 
below).  From cell cycle analysis (vide infra), complex 1 appears to damage DNA 
resulting in sub G1 fragmentation of DNA, possibly due to the cobalt interfering with 
DNA repair proteins, including zinc-finger factors.62,63   However,  one should point 
out that complex 1 toxicity occurs at doses of above 40 µM, whilst effects on 
differentiation were tested  at doses of 1 to 10 µM.  Thus whilst the DNA damage 
induced at higher doses may be cytotoxic, the little amount induced at these low doses 
may be differentiating without being cytotoxic.64  As in the case of complex 3,  in 
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complex 1 too, the complexation appears to reduce the efficacy of the metal-free 
semicarbazone ligand as a differentiating agent, whilst in this case, markedly 
increasing its cytotoxicity. 
On the other hand H8qaTSC and its cobalt(III) complex 2 (latter not shown) 
both show little activity on the NBT screen and similarly show a morphology very 
similar to the undifferentiated cells, with large nuclear-cytoplasmic ratios, nucleoli and 
many mitoses.  Again here, the stronger binding between the sulphur chalcogen donor 
atoms in the complex with cobalt(III) may reduce its ability to interact with repair 
proteins on cause DNA damage. 
One should point out that since these are abnormal leukaemia cells (and not 
normal haematopoietic progentiors) being differentiated, the variability in the 
morphology creates difficulty in understanding the nominal stage of (normal 
haematopoietic) differentiation induced by the various agents.  For this reason, three 
independent medical observers reviewed the slides to score the indicative features of 
the differentiated cells (Table S4, ESI). 
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Figure 4. Morphology of HL-60 cells upon exposure to (chalcogen)semicrbazones and 
corresponding complexes. Images are at 40x magnification. Plates a, b and c show the 
undifferentiated cells, and high power close ups of positive control differentiating 
agents, with DMSO day 5 differentiated (showing polymorphonuclear shaped nuclei) 
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and PMA day 3 differentiated (showing more condensed nuclei and marked 
vacuolation), respectively. Plates d, f and h show H8qaSC (1 µM) at day 3, H8qaSeSC 
(10 µM) at day 3 and the complex 3 (10 µM) at day 5, respectively, showing varying 
morphological evidence of differentiation.  On the other hand, exposure to H8qaTSC 
(10 µM) at day 3 (plate e) and complex 1 (10 µM) at day 3 (plate g) show little change 
from the undifferentiated state.   
 
2.6. Cytotoxic effects on tumour cell lines and non-transformed cells. 
The anti-proliferative activity of the (chalcogen)semicarbazone ligands, their 
cobalt complexes 1‒3 and reference compound CDDP was determined by the MTT 
assay after 48 h treatment on five tumour cell lines: cervix carcinoma cells (HeLa), 
lung adenocarcinoma cells (A549), colorectal adenocarcinoma cells (LS-174), breast 
carcinoma cells (MDA-MB-361), chronic myeloid leukaemia (K562), as well as one 
normal human cell line: fetal lung fibroblast cells (MRC-5). Growth inhibition effects 
of the investigated compounds, expressed in terms of IC50 values (Table 3), were 
determined from the cell survival diagrams (Figure S11, ESI).  
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Table 3. In vitro cytotoxicity (IC50 in µM)
a of the ligands and corresponding cobalt 
complexes  complexes 1‒3 determined by MTT assay after 48 h incubation. 
 IC50 (µM) 
 HeLa A549 MDA-MB-361 LS-174 K562 MRC-5 
H8qaSC 36.5 ± 3.9 >100 >100 >100 >100 >100 
H8qaTSC 75.6 ± 5.8 >100 >100 >100 >100 >100 
H8qaSeSC 6.6 ± 1.4 53.1 ± 2.8 9.2 ± 4.4 14.4 ± 2.3 4.0 ± 0.2 30.3 ± 3.6 
1 17.2 ± 1.6 24.9 ± 3.2 45.5 ± 3.4 32.9 ± 4.5 37.6 ± 0.3 39.5 ± 1.0 
2 46.2 ± 3.6 >100 >100 >100 >100 >100 
3 33.2 ± 2.2 >100 36.3 ± 0.4 >100 31.3 ± 5.9 >100 
CDDP 5.2 ± 0.3 26.2 ± 5.4 14.7 ± 1.2 22.4 ± 7.2 18.6 ± 3.3 12.1 ± 0.9 
a Values represent the mean ± SD from three independent experiments. 
 
In the investigated series of compounds, selenosemicarbazone ligand 
H8qaSeSC had the highest cytotoxicity. It showed strong cytotoxic effect on HeLa, 
K562, LS-174 and MDA-MB-361 cells, in the range of the activity of CDDP. In fact 
for a number of these cell lines it appeared considerably more toxic than this standard. 
It is worth mentioning that the ligand H8qaSeSC had a lower toxicity on normal cells 
(MRC-5), than on most of the investigated tumor cell lines.  The toxicity of H8qaSeSC 
on these untransformed MRC-5 cells was also considerably less than that of CDDP. 
The two other ligands, H8qaSC and H8qaTSC, had a low cytotoxicity on all 
investigated cell lines, reaching the IC50 in the investigated range of concentrations 
only on HeLa cells. Among the complexes, complex 1 with semicarbazone ligand 
H8qaSC showed the highest cytotoxicity,  possibly due to the cobalt(II) ion and its 
possible interaction with DNA repair proteins,65,66 which can also explain the DNA 
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damage and sub-G1 cells seen in the cell cycle analysis. Even though, this toxicity was 
still considerably less than metal-free selenium ligand on most cell lines. HeLa cells 
were the most sensitive to the action of the complex 1, while the breast cancer cells 
(MDA-MB-361) were the most resistant. Cytotoxicity of this complex on the normal 
MRC-5 cells was two times lower than the activity on HeLa cells. The 
selenosemicarbazone complex 3 showed similar cytotoxicity on HeLa, MDA-MB-361 
and K562 cells, but it was not cytotoxic to A549, LS-174 and normal cells (MRC-5) in 
the investigated concentration range.  The thiosemicarbazone complex 2 had the 
lowest activity in the investigated series of complexes, reaching IC50 only on HeLa 
cells in the investigated concentration range.  
The IC50 values (Table 3) indicate that the ligands generally show a cytotoxic 
activity in the following order:  H8qaSeSC > H8qaSC > H8qaTSC, which is consistent 
with the literature data for related (chalcogen)semicarbazones.26,30 The order of 
activity for the complexes is: 1 > 3 > 2, where complexation increased activity just in 
the case of complex 1. In this case cytotoxicity is the most likely due to the metal, as 
the ligand H8qaSC is not active. Namely, it is known that cellular uptake of cobalt is 
genotoxic due to radical-mediated DNA damage and direct cobalt interference with 
DNA repair probably by substituting zinc ions from zinc-finger proteins.63,67 Also, 
cobalt(II) ions themselves induce generation of reactive oxygen species in a Fenton-
like reaction,68 and  can replace magnesium(II) ions in enzymatic physiological 
enzyme reactions, which strongly enhance DNA cleavage.69 It can be assumed that 
cobalto(II) complex 1 is involved in oxidative damage of DNA, which is further 
supported indirectly by the results of cell cycle analysis (vide infra).  Selectivity 
toward cancer cells as compared to the normal cell line was noticed for 
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selenosemicarbazone ligand H8qaSeSC, its cobalt(III) complex 3, and cobalt(II) 
complex 1 with the semicarbazone ligand.  
 
2.7. Cell cycle analysis and mechanistic analysis of cell death 
The effects of the ligands and complexes on cell cycle progression of the HeLa 
cells were examined by flow cytometry, after continual treatment for 24 and 48 h, 
using staining with propidium iodide (PI). Examination of the histograms of HeLa 
cells (Figure S12, ESI) indicated that the ligands have different methods of action on 
dividing cells. H8qaSeSC as well as complexes 2 and 3 induce a reduction in G1 and 
an accumulation of cells in S and G2 phases of the cell cycle, indicating a G2/M arrest. 
This is a common feature of the toxic effects of a number of related chemical agents, 
including selenium containing compounds and cobalt organometallics.70-73  Toxicity of 
the complex 3 may well have been due to a reduced effect of a cell cycle G2/M 
response as compared to metal-free selenosemicarbazone ligand.  On the other hand, 
complex 1 causes a clear increase in the Sub-G1 fraction of cells, indicating a possible 
apoptosis or necrosis, probably secondary to DNA damage. As indicated above, this 
may be due to the function of the cobalt ion.  The closer interaction of the sulphur and 
selenium atoms and the cobalt(III) unlike the cobalt(II) in complex 1 may reduce this 
cobalt toxicity in these other complexes. Some toxicity can occur with cobalt(III) 
complexes,45 which may explain the cell cycle and microscopic changes seen in this 
case.    
 
An initial assessment into mechanisms of cell death induced by these 
compounds was performed using Annexin-V and PI staining both with cytometry and 
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microscopy.  Results of the microscopy (Figure S13, ESI) clearly confirm the patterns 
shown by the cell cycle analysis with H8qaSeSC and the complexes having the major 
effects and with complex 2 having effects more rapidly than others. Further details of 
perturbations of the cell cycle and apoptosis induction (Figure S14, ESI) are found in 
ESI. 
 
3. Conclusions 
Two cobalt-(chalcogen)semicarbazone complexes have been synthesized and 
characterized by X-ray crystallography. All the complexes possess octahedral 
geometry, with coordination of the ligands via quinoline and azomethine nitrogen 
atom and chalcogen donor atom. Preparation of all three cobalt-
(chalcogen)semicarbazone complexes derived from 8-quinolinecaroxaldehyde made it 
possible to study the effect of metal ion complexation and chalcogen donor identity on 
the cytotoxic activity, but direct comparison can be made just for Co(III) complexes 2 
and 3. The strong differentiation-inducing ability of the semicarbazone and 
selenocarbazone ligands may provide future differentiation agents for use either alone 
or with standard chemotherapy or DNA modifying drugs. The plan is to proceed with 
testing these effects in future on other leukaemia cell lines, using cytometry as an 
adjunct test, to see if the strong effects detected are replicated.  Differentiation 
assessment will also be performed on certain solid tumour lines, particularly brain and 
bone tumour cells. The cobalt(II) complex with semicarbazone ligand shows strong 
anti-tumour cell activity and yet minimal toxicity on normal cells. Thus further 
investigation may yield novel chemotherapeutic agents for tumours with better safety 
profiles. 
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Graphical abstract and synopsis 
 
Comparative study of (chalcogen)semicarbazones and their cobalt complexes on the differentiation of 
myeloid leukaemia cells and cytotoxicity on five human tumor cell lines and one normal human cell line 
was performed. 
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